Journal: Naunyn-Schmiedeberg's archives of pharmacology

Article Title: Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway.

doi: 10.1007/s00210-024-03004-y

Figure Lengend Snippet: Fig. 3 Effect of BrMSCs and/or saroglitazar on lipid peroxidation parameters A MDA and B SOD, the pro-inflammatory cytokines C IL-1β, D IL-10, E TGF-ß, and F serum Beclin-1 in rats with BLM-induced lung fibrosis

Article Snippet: To localize alpha-smooth muscle actin (α-SMA) protein as a marker for myofibroblasts, anti-alpha-smooth muscle actin antibody (rabbit polyclonal antibody; No. ab5694; dilution 1/50; Abcam, Cambridge, UK) (Egger et al. 2013) and with a monoclonal rabbit anti-TGFβ1 antibody (Clone TB21, MCA797, Serotec, Oxford, UK) at 1:200 dilution for TGF-β1 detection (Attia et al. 2017).

Techniques:

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Article Title: Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway.

doi: 10.1007/s00210-024-03004-y

Figure Lengend Snippet: Fig. 4 Effect of BrMSCs and/or saroglitazar on the mRNA expression genes of A TGF-β, B SMAD-3, C SMAD-7, D PPAR-γ, E PPAR-α in rats’ lungs with BLM-induced pulmonary fibrosis

Article Snippet: To localize alpha-smooth muscle actin (α-SMA) protein as a marker for myofibroblasts, anti-alpha-smooth muscle actin antibody (rabbit polyclonal antibody; No. ab5694; dilution 1/50; Abcam, Cambridge, UK) (Egger et al. 2013) and with a monoclonal rabbit anti-TGFβ1 antibody (Clone TB21, MCA797, Serotec, Oxford, UK) at 1:200 dilution for TGF-β1 detection (Attia et al. 2017).

Techniques: Expressing

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Article Title: Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway.

doi: 10.1007/s00210-024-03004-y

Figure Lengend Snippet: Fig. 10 A photomicrograph of immune-stained sections of the study groups. A CN-G showing faint expression of TGF-β1 by some cells in the alveolar septa between the alveoli and alveolar sacs. B, C BLM-G sections showing [B] Numerous cytoplasmic reactions for TGF- β1 positive immune expressed cells (arrows) within the inter- alveolar septum. C Increased TGF-β1 positive immune expressed cells (arrows) within the inter-alveolar septum. D BrMSCs-G showing some positive immune expressed cells (arrows) for TGF-β1 within the inter-alveolar septum. E Saro-G showing few positive immune expressed cells (arrows) for TGF-β1 within the inter-alveo- lar septum. F BrMSCs + Saro-G showing faint weak positive TGF-β1 immune expressed cells (arrows) within the inter- alveolar septum. (TGF-β1 X 400) (scale bar = 40 μm). G Mean values of % area of TGF-ß1 among different studied groups, one way ANOVA was used for statistical analysis. “a” means value is statistical significance when comparing CN-G with other groups, “b” means the value is statistical significance when comparing BLM-G with other groups, “c” means the value is statistical significance when comparing BrMSCs + Saro-G with other groups. The same letters mean no statistical significance dif- ference

Article Snippet: To localize alpha-smooth muscle actin (α-SMA) protein as a marker for myofibroblasts, anti-alpha-smooth muscle actin antibody (rabbit polyclonal antibody; No. ab5694; dilution 1/50; Abcam, Cambridge, UK) (Egger et al. 2013) and with a monoclonal rabbit anti-TGFβ1 antibody (Clone TB21, MCA797, Serotec, Oxford, UK) at 1:200 dilution for TGF-β1 detection (Attia et al. 2017).

Techniques: Staining, Expressing

Journal: Cell discovery

Article Title: Single-cell and spatial dissection of precancerous lesions underlying the initiation process of oral squamous cell carcinoma.

doi: 10.1038/s41421-023-00532-4

Figure Lengend Snippet: Fig. 7 mIHC staining showing clinical relevance and cellular crosstalk landscape for OSCC initiation. a, b mIHC staining of two groups of selected markers (Group 1: PD-L1, TGFβ1, VEGFA, CD68, and PanCK; Group 2: APOE, CD68, FOXP3, OX40, and PanCK) in the samples of de novo OLK (a) and recurrent OSCC with OLK (b). Those recurrent OSCC samples with recurrent OLK were taken from patients who had OLK-derived OSCC before. The patients were under a clinical trial focusing on anti-PD-1 antibody treatment. Scale bars: 200 μm. Statistical quantification is shown in each image. c Flowchart showing the induction of OSCC by 4NQO in C57BL/6 mice and intraperitoneal injection of anti-PD-1/anti-TGFβ/anti-PD-1+ anti-TGFβ antibody in each treatment group. d Representative intraoral lesions on the tongues of mice in each group. e Macroscopic lesions on the tongues of each group. The dotted circle indicates cauliflower-like lesions. f Statistical results for quantification of the macroscopic cauliflower-like lesions in each treated and untreated group. A two-tailed Student’s t-test for the P values. *P < 0.05. g Potential maps on malignant transformation of epithelial cells and dynamic crosstalk between epithelial cells and the TMEs during OSCC initiation.

Article Snippet: Mice received 200 mg anti-PD-1 antibody (InVivoMAb, BioXCell, anti-mouse-PD-1 antibody, BE0146, clone RMP1-14) and 300mg anti-TGFβ antibody (InVivoMAb, Selleck, anti-human/mouse-TGFβ antibody, A2113, clone 1D11.16.8) per injection intraperitoneally.

Techniques: Staining, Derivative Assay, Injection, Two Tailed Test, Transformation Assay

Journal: BMC Nephrology

Article Title: Analysis of high glucose injury using human induced pluripotent stem cell-derived kidney organoids

doi: 10.1186/s12882-025-04566-6

Figure Lengend Snippet: High glucose increases kidney organoid fibrosis. ( A ) Sirian staining of kidney organoids, ( B ) Heatmap of mRNA expression for molecules related to TGFB1 , CTGF , vimentin , COL4 , COL1 , and fibronectin , n = 3, ( C ) Immunofluorescence detection of TGF-β1 protein expression (marked in red) in kidney organoids 72 h after intervention. Scale bar = 20 μm, magnification = 400×, ( D ) Immunofluorescence detection of COL4 protein expression in kidney organoids 72 h after intervention. Scale bar = 20 μm, magnification = 400×, ( E ) Statistical analysis of the average fluorescence intensity of TGF-β1, * P < 0.05, n = 4. ( F ) Statistical analysis of the average fluorescence intensity of COL4, * P < 0.05, n = 4. ( G ) Positive area of Sirius staining of kidney organoids after 24-hour high glucose intervention. ( H ) Positive area of Sirius staining of kidney organoids after 72-hour high glucose intervention

Article Snippet: TGF-β1 , BOSTER , MA00019.

Techniques: Staining, Expressing, Immunofluorescence, Fluorescence

Journal: International Journal of Ophthalmology

Article Title: Pirfenidone suppresses the abnormal activation of human Müller cells after platelet-derived growth factor-BB stimulation

doi: 10.18240/ijo.2019.07.04

Figure Lengend Snippet: A: The cells of the normal group and the model group were respectively treated by 0, 0.2 and 0.3 mg/mL pirfenidone. The relative mRNA levels of TGF-β1, TGF-β2 and PEDF were determined by real-time PCR. Results are shown as indicated. The expression levels of TGF-β1, TGF-β2 and PEDF under the indicated treatment of pirfenidone were detected by Western blotting (B) and immunofluorescence (C). Green fluorescence, for the indicated proteins; blue fluorescence for the nucleus. aP<0.05 vs normal+0 mg/mL pirfenidone group, bP<0.01 vs normal+0 mg/mL pirfenidone group, cP<0.0001 vs normal+0 mg/mL pirfenidone group; dP<0.05 vs model+0 mg/mL pirfenidone group, eP<0.01 vs model+0 mg/mL pirfenidone group, fP<0.0001 vs model+0 mg/mL pirfenidone group; gP<0.05 vs model+0.2 mg/mL pirfenidone group, hP<0.01 vs model+0.2 mg/mL pirfenidone group, iP<0.0001 vs model+0.2 mg/mL pirfenidone group.

Article Snippet: The expression of TGF-β1, TGF-β2, PEDF, and β-actin was respectively tested by anti-TGF-β1 antibody (Boster, USA, {"type":"entrez-nucleotide","attrs":{"text":"A04630","term_id":"411029","term_text":"A04630"}} A04630 ), anti-TGF-β2 antibody (Boster, USA, {"type":"entrez-protein","attrs":{"text":"A00892","term_id":"77211","term_text":"pir||A00892"}} A00892 ), anti-PEDF antibody (Abcam, USA, ab233120) and anti-β-actin antibody (Invitrogen, USA, PA1183).

Techniques: Real-time Polymerase Chain Reaction, Expressing, Western Blot, Immunofluorescence, Fluorescence